Timothy A. Springer, Ph.D. Founder; Board of Directors; Co-chair, Scientific Advisory Board Timothy A Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Timothy A. Springer, Ph.D.

Founder; Board of Directors; Co-chair, Scientific Advisory Board

Timothy A Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Andrew Kruse, Ph.D. Co-Founder; Co-chair, Scientific Advisory Board Andrew Kruse, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.  

Andrew Kruse, Ph.D.

Co-Founder; Co-chair, Scientific Advisory Board

Andrew Kruse, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.

 

James Love, Ph.D. Chief Operating Officer Dr. Love was educated at Oxford and Cambridge Universities, and was trained as a structural biologist at the MRC-LMB. After his postdoctoral work, he become the Head of Research for the New York Consortium on Membrane Protein Structures, which utilized high-throughput protein production methods to express, purify and screen thousands of integral membrane proteins for structural studies. Dr. Love then pioneered high- throughput protein expression and purification techniques at Albert Einstein College of Medicine, before joining ATUM (f.k.a DNA2.0) as director of expression technologies, where he set up a state-of-the-art lab, which successfully produced thousands of purified mammalian proteins.  

James Love, Ph.D.

Chief Operating Officer

Dr. Love was educated at Oxford and Cambridge Universities, and was trained as a structural biologist at the MRC-LMB. After his postdoctoral work, he become the Head of Research for the New York Consortium on Membrane Protein Structures, which utilized high-throughput protein production methods to express, purify and screen thousands of integral membrane proteins for structural studies. Dr. Love then pioneered high- throughput protein expression and purification techniques at Albert Einstein College of Medicine, before joining ATUM (f.k.a DNA2.0) as director of expression technologies, where he set up a state-of-the-art lab, which successfully produced thousands of purified mammalian proteins.